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Spatial and temporal regulation of the pericellular proteolytic environment by local growth factors, such as EGF and TGF-
β, initiates a wide repertoire of cellular responses coupled to a plasmin/matrix metalloproteinase (MMP) dependent stromal-
remodeling axis. Cell motility and invasion, tumor metastasis, wound healing, and organ ﬁbrosis, for example, represent diverse
events controlled by expression of a subset of genes that encode various classes of tissue remodeling proteins. These include
members of the serine protease and MMP families that functionally constitute a complex system of interacting protease cascades
and titrated by their respective inhibitors. Several structural components of the extracellular matrix are upregulated by TGF-β
as are matrix-active proteases (e.g., urokinase (uPA), plasmin, MMP-1, -3, -9, -10, -11, -13, -14). Stringent controls on serine
protease/MMP expression and their topographic activity are essential for maintaining tissue homeostasis. Targeting individual
elements in this highly interactive network may lead to novel therapeutic approaches for the treatment of cancer, ﬁbrotic diseases,
and chronic wounds.
1.Introduction
Epithelial transdiﬀerentiation or cellular “plasticity” refers
to a specialized morphogenetic switch typiﬁed by loss
of normal epithelial properties, a gain in the expression
of genes generally restricted to the mesenchymal lineage
and conversion of sessile, nonmotile cells to a migratory
phenotype [1, 2]. While essential during development and
organogenesis(i.e.,embryonicpatterning)(alsotermedType
1 transition), this process is relatively limited in the adult
organism, occurring during wound healing and regenerative
repair [3–5] or, more atypically, in tissue ﬁbrosis (Type
2) and tumor metastasis (Type 3) [6–9]. Whether a true
epithelial-mesenchymal-myoﬁbroblast transition, or a more
intermediate state of transdiﬀerentiation, contributes to the
pathophysiology of human ﬁbrotic disease, however, is the
subject of considerable debate [10–16].
The temporal and spatial regulation of cellular plasticity,
as well as the subsequent restitution of an epitheloid
phenotype, is likely a collective response to speciﬁc growth
factors (individually or in combination) and informational
cues from the extracellular environment [2, 8, 17]. The
nature of the initiating stimulus as well as the underly-
ing pathology and associated genetic reprogramming also
impact temporal control versus persistence of the plastic
restructuring. Epidermal growth factor receptor (EGFR)
ampliﬁcation and alterations in the transforming growth
factor-β (TGF-β) signal transduction network, for example,
frequently accompany epithelial tumor progression from a
benign or noninvasive lesion to an aggressive, metastatic2 Biochemistry Research International
carcinoma [18–20]. During this transition, and despite
increased autocrine/paracrine expression of TGF-β,c e l l s
often become refractory to the normally growth-suppressive
eﬀects of TGF-β family members due, in part, to down-
regulation of TGF-β receptors and/or anomalies in TGF-
β-initiated signaling pathways [20, 21]. Similarly, in tissue
ﬁbrotic disorders, diﬀerentiation, proliferation, and subse-
quent interstitial accumulation of “ﬁbroblastoid” elements
in the kidney and lung (two of the most well-studied organ
systems in the context of ﬁbroproliferative disease) appear to
resultfromaprogrammed,butpersistent,responsetoseveral
proﬁbrotic cytokines, the most prominent of which is TGF-β
[11].
2 .T h eSe rin eP r o t eas e - M atrix
MetalloproteinaseCascadein
Tissue Remodeling
TGF-β promotes cellular motile and invasive properties, as
well as the emergence of the plastic cohort, through expres-
sion of a subset of genes that encode various classes of stro-
mal remodeling proteins [22, 23]. These include members
of the serine protease and matrix metalloproteinase (MMP)
families and their respective inhibitors which, paradoxically,
support matrix disruptive as well as stabilizing processes.
Several structural components of the extracellular matrix
[24, 25] are, in fact, upregulated by TGF-β as are matrix-
active proteases (e.g., urokinase (uPA), plasmin, MMP-1,
-3, -9, -10, -11, and -13) and protease inhibitors [26–29].
Stringent controls on serine protease/MMP transcription,
duration of expression, and topographic activity are essential
for maintaining tissue homeostasis in the intact organism
as well as in organotypic systems [30]. Proteolytic networks
within the pericellular microenvironment, moreover, are fre-
quently activated by the conversion of plasminogen to plas-
min, a broad-spectrum protease. Plasmin, in turn, targets
stromal elements directly while also activating several MMPs
triggering a complex cascade leading to matrix degradation
[31]. Upstream plasmin generation substantially impacts
MMP-dependent stromal remodeling and, thereby, cellular
invasive traits. Such in vivo pathologies can be elegantly
modeled in vitro upon addition of EGF + TGF-β1t om a l i g -
nant human epithelial cells to mimic the frequently observed
TGF-β1 elevation in the tumor microenvironment and
ampliﬁed EGFR signaling characteristic of late-stage cancers
[32]. Combined EGF + TGF-β1 costimulation resulted in
the synergistic upregulation of a deﬁned set of proinvasive
genes, the most prominent of which encodes plasminogen
activator inhibitor-type-1 (PAI-1 or SERPINE1, the clade E
member 1 of the family of serine protease inhibitors). PAI-
1 is a potent and fast-acting inhibitor of uPA-dependent
plasmin production [22, 23]. This ﬁnding is of considerable
translational relevance since increased PAI-1 levels often
occur in concert with epithelial cell plasticity, paralleling
the requirement for enhanced cell motility [33]. The ability
of TGF-β and/or EGF to increase PAI-1 expression in
s e v e r a lc e l lt y p e s[ 26, 34] provides a potential mechanism
for upstream titration of the MMP cascade via controlled
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Figure 1: The plasmin/MMP axis in pericellular proteolytic con-
trol. uPA, tethered to its receptor (uPAR), converts plasminogen
receptor- (PlgR-) bound plasminogen to the broad-spectrum pro-
tease plasmin that, in turn, activates several MMP family members.
Collectively, plasmin and MMPs regulate the extent, duration, and
locale of stromal remodeling.
generation of pericellular plasmin consequently modulating,
both in time and space, extracellular matrix proteolysis and
stromalremodeling. Indeed, elevatedPAI-1 levelscommonly
accompany the development of such diverse pathologies
as tumor progression, inﬂammation, hypertrophic scarring,
atherosclerosis, thrombosis, myocardial infarction, diabetes,
and the obesity-associated metabolic syndrome [11, 31, 35–
40].
3.FocalProteolysis:Regulation ofCell
MigrationandSignaling
The contribution of PAI-1 as a promoting element in
various disease states is thought to occur through multiple
avenues involving proteolytic control, an essential aspect
in the maintenance of a “stromal scaﬀold” that impacts
cell survival, growth and transdiﬀerentiation, cellular motile
processes, and signal transduction. Focal proteolysis within
the pericellular microenvironment is controlled primarily
through mechanisms that regulate plasminogen activation
at the cell surface that, in turn, aﬀect MMP activation
downstream with subsequent engagement of a complex
tissue remodeling program [41]( Figure 1).
Importantly, focalized proteolysis promotes the discrete
release of several physiologically signiﬁcant bioactive frag-
ments and growth factors from the stromal compartment
that inﬂuence cell proliferation and cell migration. MMP-
dependent generation of degradation products of extra-
cellular matrix structural elements, for example, aﬀects
both angiogenic and antiangiogenic activities with an
impact on endothelial motile characteristics under in vivo-
relevantconditions[42].MMP-2andMMP-9cleavecollagen
IV, exposing cryptic epitopes that stimulate angiogenesisBiochemistry Research International 3
[43, 44] while matrikines such as arrestin, canstatin, tum-
statin and metastatin, also generated from collagen IV, are
antiangiogenic [41, 42]. Proteolytically derived fragments
of collagen XVIII (endostatin and neostatin), collagen VIII
(vastatin), collagen XV (restin), and perlecan (endorepellin)
similarly exhibit anti-angiogenic properties [41, 42]. These
fragments often compete with intact extracellular matrix
molecules for binding to various cell surface receptors as
one mechanistic basis for their eﬀects [41]. A particularly
important event involves the MMP-dependent release of
laminin-332 fragments that promote epithelial cell migra-
tion. Indeed, the recombinant domain III of the laminin-
332 γ2 chain (processed from laminin-332 by MT1-MMP,
a membrane type 1 MMP, and MMP-2) binds to EGFR
and initiates signaling events which culminate in enhanced
cell motility [45–47]. Similarly, MMP-based proteolysis of
ﬁbronectin yields fragments that aﬀect migration (MSF) [41,
42, 48], angiogenesis (anastellin) [49, 50], cell proliferation,
and diﬀerentiation [41]. Stromal PAI-1 is itself a substrate
for several extracellular proteases including elastase, MMP-
3 and plasmin resulting in the generation of rather speciﬁc
PAI-1 cleavage products [32, 33, 51–53]. Such “cleaved”
PAI-1 is unable to bind its target plasminogen activators
uPA and tissue-type PA (tPA) to inhibit plasmin-based
proteolysis but retains the ability to bind to the low-density
lipoprotein receptor-related protein-1 (LRP1) where it eﬀec-
tively augments cell migration through a uPA/tPA complex-
independent interaction [54]. The mechanistic basis for this
response is not clear but appears to involve LRP1 function
as a key signaling mediator in several intracellular pathways
as a consequence of, in part, interactions with multiple
adaptor and scaﬀolding proteins [55]. LRP1 ligand binding
and/or complex formation with additional surface receptors
also activates speciﬁc mitogen-activated protein (MAP) and
src kinases [56–60] stimulating cell proliferation [58, 61–
63] and migration [54, 56, 64] with the motile outcome
dependent on Rho family GTPases [64]. Alternatively, PAI-1
can also initiate signaling events that impact cell migration
through engagement of LRP1 and the related very low-
density lipoprotein receptor [65]. Indeed, diﬀerent confor-
mations of PAI-1 (active, latent as well as plasmin- or MMP-
cleaved) all interact with LRP1 to enhance cell migration
into physiological scaﬀolds or stromal equivalents [66]. The
three forms of PAI-1 appear to increase LRP1-dependent cell
motility via speciﬁc engagement of the Jak/Stat1 signaling
pathway [54, 67, 68]. These data are consistent with recent
ﬁndings that the migratory response to TGF-β1+E G F
in transformed human epidermal keratinocytes is PAI-1-
dependent [22, 23] and that stabilized (i.e., long half-life)
recombinant PAI-1 alone, in the absence of added growth
factors, stimulates motility comparable to that attained by
growth factor supplementation (Figure 2). The receptor-
associated protein (RAP), an LRP1 antagonist which binds
LRP1 and blocks interactions with all known ligands includ-
ing PAI-1, inhibits the migration-promoting eﬀects of PAI-1
in chemotactic and wound healing assays [54]a n de ﬀectively
inhibited EGF-stimulated motility, which is known to be
d e p e n d e n to nL R P 1 / P A I - 1( Figure 2) .W h i l ea c t i v eP A I - 1i s
routinely cleared from the extracellular environment in a
complex with uPA/uPAR/LRP1, latent and cleaved species of
PAI-1, with a preserved motile function, remain embedded
in the matrix likely serving as a reservoir to maintain
cell movement [33]. Collectively, these data illustrate that
serine protease/MMP-initiated proteolytic processing of the
extracellular environment impacts multiple aspects with
regard to the regulation of cell motility.
4. Tumor Microenvironment and
CutaneousWound Repair:Sitesof
Interacting Proteolytic Cascades
Ampliﬁed MMP expression correlates with tumor aggres-
siveness, metastasis, and poor prognosis [69]. Not sur-
prisingly, therefore, recent studies implicate several MMPs,
including MMP-3, -7, -9, and -28 in triggering plasticity-
related processes [69]. The combination of TGF-β +E G F
eﬀectively promotes epithelial-to-mesenchymal transition
and upregulates MMPs-1, -3, -9, -10, and 14 [22, 23, 70,
71], coupling cellular invasive potential to a plasmin/MMP-
10/MMP-1-dependent collagen-remodeling axis. As a proof-
of-concept, an acute collagenolytic phenotype, linked to
plasmin-dependent activation of stromelysin-2 (MMP-10),
accompanies costimulation of malignant (HaCaT II-4) ker-
atinocytes with TGF-β1 and EGF coincident with collagen
invasion [32]( Figure 3). MMP-10, which is generally limited
to epithelial cells [29, 72], targets proMMPs-1, -7, -8, -9, and
-13, as well as collagens type III, IV, and V, gelatin elastin,
ﬁbronectin, proteoglycans, and laminin [30, 31]. MMP-10
induction in response to TGF-β + EGF suggests that precise
control over its levels and activation are likely critical for
cutaneous homeostasis. MMP-10, in fact, is not evident in
intact skin but expressed during cutaneous injury repair
localizing to migrating keratinocytes at the wound edge,
suggesting a role in invasive behavior [73].
Similar to other systems [29, 71, 72, 74], MMP-10 and
MMP-1 are upregulated in TGF-β1 and/or EGF-stimulated
human malignant keratinocytes maintained on collagen
substrates [32]. The proenzyme forms of MMP-1 and MMP-
10 are plasmin substrates. Following MMP-10 inhibition,
however, the residual level of active plasmin-generated
MMP-1 appears insuﬃcient to initiate collagen dissolution
[32]. This reﬂects the established ability of MMP-10 to
“superactivate” or enhance MMP-1-dependent proteolysis,
as well as that of MMP-8 and -13, and signiﬁcantly enhances
collagenolytic activity over that observed with plasmin alone
[72, 75]. Although plasmin is clearly an important primary
activator of this complex cascade, the cathepsins, like MMPs,
also associate with tumor cell invasion. This is particularly
true for the cysteine proteinases cathepsin L and cathepsin
B, which degrade type-1 collagen and mobilize several
MMPs (including MMP-1), respectively [76]. Inhibition of
cysteine cathepsins had no eﬀect, however, on collagen
dissolution in the HaCaT II-4 model while serine proteinase
blockade eﬀectively attenuated collagen degradation [32].
These data reinforce the critical role for active plasmin,
and not cathepsins, in the initiation of collagen degradation
by TGF-β1 + EGF and are consistent with observations4 Biochemistry Research International
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Figure 2: HaCaT II-4 cultures were grown to conﬂuency, monolayers washed 2X with PBS and incubated in serum-free DMEM for 24
hours. Cultures were scrape-wounded with a P1000 pipette tip using a constant-pressure press, washed 3X to remove liberated cells, and
returned to serum-free medium without (control) or with the following additives: EGF (10ng/mL), PAI-1 (40mM), RAP (5μg/mL), or the
combination RAP (5μg/mL) + EGF (10ng/mL). Initial wound sizes were measured with a calibrated ocular grid at multiple marked sites; 24
hours later, the injury sites were remeasured at the identical marked regions used to calibrate the initial denuded area. The extent of wound
site closure (motility index = grid distance migrated) was plotted on the y-axis for each condition; shown are data from 2 representative
experiments. PAI-1 stimulated cell migration to the same extent as EGF. Ctl: control unstimulated cultures.
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Figure 3: Model ofTGF-β1+EGF-enhanced plasmin-dependent collagen matrixremodelingand development of aninvasive phenotype. In
the presence of plasmin, increased MMP-10 levels promote MMP activation creating a proteolytic axis that accelerates collagen degradation
through “superactivation” of MMP-1. STAT3 may act as a positive switch in this process, via promotion of EGF-stimulated proMMP-10
expression [23]. Upregulation of PAI-1 in response to TGF-β1 + EGF may subsequently shift this proteolytic balance, enabling PAI-1 to
“titrate” the extent and locale of collagen matrix remodeling to facilitate stromal invasion. Indeed, PAI-1 induction occurs early in this
transition and required for stimulated migration and collagen invasion since PAI-1 knockdown (with siRNA constructs) eﬀectively inhibited
both events [22].
regardingthedownregulationofseveralcathepsinsbyTGF-β
[77].
The coupling of keratinocyte-based type-1 collagen
degradation with plasminogen activation implicates inter-
mediates other than MMP-10, including MMP-13 [78, 79].
The available evidence indicates the existence of a functional
overlap between MMP-13 and uPA in the context of
cutaneous wound repair, at least in the murine system [80].
Contrary to what has been observed in primary human
keratinocytes, MMP-13 expression is, in fact, linked toBiochemistry Research International 5
transformation of human keratinocytes (i.e., HaCaT cells
and various derivatives) [27, 74] and actually enhanced
following addition of TGF-β1 to HaCaT II-4 cells [32,
74]. Use of a physiological 3-D reconstruct model of the
stromal microenvironment, however, led to the conclusion
thatthecombinationofTGF-β1+EGFdoesnotsigniﬁcantly
upregulate MMP-13 protein in HaCaT II-4 cells but, instead,
leads to a robust induction of MMP-10 [32]. This disparity
may be due in part to diﬀerences among the ras-HaCaT
variants in MMP expression programs [81], TGF-β/EGF
receptor crosstalk [11, 71, 82], or culture in 2D versus a more
complex 3D stromal-equivalent system [32].
Modelsofcutaneousinjuryrepairhaveshedconsiderable
light on the complex roles of growth factors and cascading
protease systems in the tissue response to trauma. Generally,
both TGF-β1 and EGF levels increase substantially following
acute injury, partially due to their release from platelet α
granules, but also through increased cellular expression, par-
ticularlyatthewoundedge[83].Thesegrowthfactorsappear
critical to the initial stages of cutaneous tissue regeneration
through promotion of keratinocyte migration, as well as
proliferation [84–87]. TGF-β1 and EGF upregulate MMP-
10 in keratinocytes [72, 88] and, during cutaneous wound
repair, MMP-10 is speciﬁcally localized to cells in the migrat-
ing tongue where it appears to enhance migration [87, 88].
Similarly, uPA and MMP-3, -9, and -13 all localize to leading
edge epidermal cells [80]. Overexpression of constitutively
active MMP-10 in the epidermis, moreover, has deleterious
eﬀects on the coordinated migration of keratinocytes into
the wound bed; an eﬀect attributed to excessive laminin-
5 (laminin-332) processing [87]. Unconstrained MMP-10
activity leads to excessive collagenolysis [32] which impacts
negatively on cell migration and, ultimately, the restoration
of tissue integrity. Notably, PAI-1 expression also increases in
keratinocytes at the wound margin and is deposited into the
migration tracks of these cells, suggesting that this SERPIN,
as well, plays an integral role in regulating directional migra-
tion and wound closure [89–92]. Coordinate upregulation of
proteolytic enzymes such as the MMPs, together with the
upstream inhibitor of plasmin generation (i.e., PAI-1) by
individual growth factors provides an exquisite mechanism
for ﬁne control of focal proteolysis to facilitate optimal cell
motility in complex environments.
5. Conclusions
Increases in epithelial MMP-10 expression, and its subse-
quent activation by catalytic-levels of plasmin, mobilize an
MMP cascade creating a proteolytic axis that accelerates
collagen degradation through “superactivation” of MMP-1
while enhancing stromal proteolysis largely by MMP-7, -8,
-9, and -13. Upregulation of the serine protease inhibitor
PAI-1, in tumor cells, in mesenchymal cells within the tumor
microenvironment as well as by “wound-stimulated” epithe-
lial cells, may subsequently shift this proteolytic balance to
optimize creation of a migratory “scaﬀold.” The available
data clearly implicate PAI-1 as a major upstream modulator
ofauPA→plasmin-generatingsystemthatexertsﬁnecontrol
over the MMP-dependent pericellular proteolytic cascade.
In this context, PAI-1 may “titrate” the extent and locale
of collagen matrix remodeling to facilitate cellular invasion
within the stromal compartment as part of the metastatic
and tissue repair programs. Further clariﬁcation of the
complexity of controls and the extent of interdependency
of individual cascading “arms” in this highly interactive
network of matrix proteases and protease inhibitors will be
necessary for the rationale design of focused therapeutic
approaches for the treatment of cancer, ﬁbrotic disorders
and chronic wounds. Assessments of MMP inhibitors in
clinical trials is already ongoing. Indeed, the emergence of
uPA and PAI-1 as signiﬁcant level-of-evidence-1 prognostic
markers of overall survival in breast cancer is well established
[93]. The development of small molecule inhibitors of PAI-1
(i.e., tiplaxtinin or PAI-039) that eﬀectively attenuate aortic
remodeling in the context of vascularinjury [94] suggest that
targeting this SERPIN may have translational implications
for treatment of chronic ﬁbrotic and, perhaps, malignant
disease.
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